Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia (AML)
Biotech
Ipsen inks €1B buyout of French biotech ImCheck
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck for its investigational cancer combo therapy in a deal worth up $1.16 billion.
Gabrielle Masson
Oct 22, 2025 10:33am
Schrödinger abandons CDC7 inhibitor linked to 2 patient deaths
Aug 14, 2025 8:23am
Sellas’ AML asset tied to 50% response rate in certain patients
Jul 15, 2025 10:34am
Vor Bio to wind down, laying off most staff
May 8, 2025 10:50am
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
Ryvu loses 30% of staff in focus on ph. 3 blood cancer trials
Feb 25, 2025 10:00am
